Infinity Pharmaceuticals said today it will eliminate 58% of its workforce—100 employees—and shut down several clinical trials in a restructuring touched off by the end of a nearly 2-year-old ...
– Companies to Jointly Develop and Commercialize Duvelisib in U.S., with Equal Profit Share; Infinity to Receive Royalties on Sales Outside the U.S. – – Infinity to Host Conference Call Today at 8:30 ...
CAMBRIDGE, Mass., Sept. 25, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback